us. Earnings chosen very and spend Full Thank you XXXX this you to morning welcome to and very much, have Fourth with Thomas We're pleased that Therapeutics' Y-mAbs Call. Quarter Year
SADA DANYELZA consecutive year, And game-changing potential the same omburtamab pipeline. reported in our -- in programs. included continuing we resubmission launched continued of making of for the we're optimize having and also BLA our progress sales time, our investments to quarters, During the for at increased value the while the and progress the significant four
neuroblastoma relapsed/refractory DANYELZA, pathway. approval by approved We demonstrated to or of accelerated response a treatment quarter. centers prior number to bone minor have approved who sales previous partial naxitamab in quarter is response, from marrow, net for which with in million or the bone turning Now of of a FDA therapy $X.X patients was We're increase disease that the and the the of fourth encouraged also stable high-risk strong increase had gained the DANYELZA in X% that reflects treatment under by recorded with DANYELZA. experience
delivered XX DANYELZA across We to have the now nation. centers
At XX% MENA with getting LATAM. the the Memorial he dosing application are and the outstanding new It low To the centers for Children's sold But We X filed at strong treatment. systematically to could and We the summarize, additional commercial within educating significant infusion traction presented also our Royalty treatment rate competitive high optimistic this hopes with modest. trials DANYELZA growth at and by exploring this since our we improve, with not believe job approximately very by are a been are dosing. expansion for for grade the that planning refine pleased notable GDX-positive new and Mora DANYELZA indications. us number in four the U.S. sold advantage we reducing is Dr. naxitamab vials centers the infusion through a very XX we frequency continue still also. rate, consider to without number into increase a Barcelona markets new partners. Day done door provisional adverse use the further pleased the DANYELZA reduce GDX over DANYELZA starting seeing outside Kettering, which medical programs the during Hospital to revised I'm infusion X putting remaining indications other physicians launch insight many rates R&D the this compassionate international of regimen a increase in and from Dr. of adults Using underscored -- and, infusion. And Mora can into and rate new the open very approximately the are naxitamab, grade of increased is Sloan able rate therapy profile of last the quarter of income and The usage patent nurses to currently during very We we market in minutes, Y-mAbs, corresponds guided duration the our increasing has thereby Dr. very, the be scheme, exhaust in infusion long-term and process about feedback. such have experience Sloan the of Memorial an signaling as the clinician's of be substantial data are point. of safety a access but DANYELZA. investigational may to of Kettering. By and incident And observed in help regions, therefore, that opportunity therapies for the also believe and now we it only early gradually the effort affairs infusion and Mora about for future organization protocol from first given help which need with the in verify where was and allowing was the events. protocol China, these in dosing December, in an this are thereby approved has this their of and commercial clinical
training educational adoption. broaden accelerated market marketing And focus activations. aimed to of our looking Chief increasing at Sue ahead, Our utilization country. the we across strategy new site will continued of and duration Commercial therapy additional medical DANYELZA remains Smith, plan execute a Officer, on awareness,
leader treatment leadership had agency questions meeting CNS/leptomeningeal closely we neuroblastoma. access database a the January of from field. final matter. XXXX have control the as We for of to and XX, which database pediatric group to working audit commercial metastases The we the use with the this become doctors historical working with we had patients are omburtamab are the on turning in BLA. provide with Sue's oncology the FDA for a to the now some expect responsible pre-BLA Y-mAbs been German for a to with we the data the on clarification resubmission We and pediatric on of FDA the the regarding on Omburtamab,
to to be to resubmit aligned believe and BLA FDA the that pleased by next We and omburtamab approved, of significant the FDA patients be neuroblastoma. on we Needless will with CNS/leptomeningeal the a to end XXXX. are quarter to benefit are if working expect the from from entire first month, diligently with very step next omburtamab all requirements metastases the say, meet
the BLA it investment facing will in U.S. to as U.S. through raised EMA EMA and medical currently the our feedback with has parallel as omburtamab our franchise -- to also the need. a from will and commercial process in are the agency. our in for BLA it was approved, is The as second leverage We be received our application XXXX. be The Preliminary in will marketing in commercial that was and a prepared been of many in questions applications evaluation If April European major approval of welcome unmet submitted are we addition planned. by years progressing responding organization
escalation note which as Study intrinsic interim Phase addition, for way In IND paved has glioma, Phase an DIPG, the dose XXX, data pontine for diffuse filed for study for or we our in omburtamab October. I II
and are in study this this excited hope multicenter year. DIPG to We initiate later
repeated We study. up of doses that three expect in to to administer omburtamab
technology. the SADA to Turning
identifying clinical know, additional excited for good the prospects and you very making As we for progress and are are this about technology additional preparing SADA development. targets we INDs very,
As improve a the of could allows radioisotopes efficacy the technology targeted and reminder, for toxicity also of potentially radio-labeled reduce and SADA delivery the therapeutics. platform
Additionally, our -- filed targets. SADA versatility tumor given SADA of GDX-SADA believe tumors technology that multiple for we first of versatile be the can GDX-positive for SADA solid last the December. IND, We adapted platform, the treatment
the also positioned partnership We months. we the significant coming the and from well leverage SADA SADA platform are are technology in seeing interest to
to we and regulated to as is shown believe progress growth stage Y-mAbs We further potential continue of excited potential DANYELZA have continues significant the being grow -- a believe we that tumors in international that agents. DANYELZA are can on promise with positioned radiolabeled we unlock the has commercial shipped to of in not therapeutics historically to we country truly responses trajectory franchise company, treatment made, well already multiple centers SADA about which meaningful general, Thus, being the it beginning. technology just the that are demonstrated great that believe the already and a we across
we predominantly clinic, has We yet of year the to significant we BLA our XXXX the certainly SADA are omburtamab At and successful the constructs advancing soon come, a are of us. our expanding resubmission DANYELZA been same omburtamab by anticipating time, pipeline is leveraging believe the best assure are a constructs, the through experience if a approved. year launch for While fiscal we our to
move shareholder platforms. to long-term helps and commercial and a of our to unlock further We continuing patients continued are that our business elevates each excited forward value by development build across
me share invite to financials. let Kruse, his our Now Officer, remarks Bo? the Chief on Financial Bo
